New Antiviral Treatment for Chronic Hepatitis B

  • Man-Fung Yuen
  • Ching-Lung Lai
Conference paper


Prolong treatment maintaining a low viraemic state may reduce the risk of longterm complications of chronic hepatitis B. Lamivudine has profound anti-viral effect with three to four logarithmic reduction of hepatitis B virus (HBV) DNA level after 1 year. Its long-term use is, however, associated with the emergence of drug resistant virus (YMDD mutations). High pretreatment alanine aminotransferase (ALT) levels and HBV DNA levels are associated with earlier HBV DNA breakthroughs due to YMDD mutations. In addition, HBV DNA levels over 10’ copies/ml at 6 months of lamivudine therapy are also associated with the chance of YMDD mutations. There are now several new nucleoside analogues currently being studied by phase II/ III clinical trials. (3-L-2’-deoxythymidine (LdT) and 13L-2’-deoxycytidine (val-LdC) are unsubstituted (3-L-2’deoxynucleosides with highly potent, selective and specific anti-HBV activity. In a phase I/ II dose escalation trial of LdT, there was a dose proportional response in the reduction of HBV DNA levels. Maximal reduction of 3.4-3.8 logs was achieved in the dose of 400-800 mg daily. In an ongoing phase IIb clinical trial, LdT with doses of 400 and 600 mg daily caused significantly higher greater HBV DNA reduction compared to lamivudine 100 mg daily monotherapy (-6.1 logs vs. -4.7 logs respectively, p=0.05). LdT is also very safe and without significant side effects. Trials using combination therapy combining immunomodulators and nucleoside analogues or combining different nucleoside analogues are currently being conducted.


Nucleoside Analogue HBeAg Seroconversion Adefovir Dipivoxil Lamivudine Therapy Lamivudine Treatment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Yuen MF, Lai CL. Treatment for chronic hepatitis B. Lancet 2001;1:232–241.CrossRefGoogle Scholar
  2. 2.
    Yuen MF, Yuan HJ, Hui CK, Wong DKH, Wong WM, Chan AOO, Wong BCY, et al. A large population study of spontaneous HBeAg seroconversion and acute exacerbation of chronic hepatitis B infection: Implications for antiviral therapy. Gut 2003;52:416–9.Google Scholar
  3. 3.
    Yuen MF, Lai CL. Natural history of chronic hepatitis B infection. J Gastro Hepatol 2000; 15(Suppl):20–25.CrossRefGoogle Scholar
  4. 4.
    Yuen MF, Yuan HJ, Hui CK, Wong WM, Lai CL. Determinants for the development of cirrhosis-related complications and survival in patients with chronic hepatitis B infection. Hepatology 2002;36(4 Pt 2):525AGoogle Scholar
  5. 5.
    Lai CL, Yuen MF. Profound suppression of hepatitis B virus replication. J Med Virol 2000;61:367–73.PubMedCrossRefGoogle Scholar
  6. 6.
    Lai CL, Chien RN, Leung NWY, Chang TT, Guan R, Tai DI, Ng KY, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998;339:61–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HWL, Goodman Z, Crowther L, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256–63.PubMedCrossRefGoogle Scholar
  8. 8.
    Schalm SW, Heathcote J, Cianciara J, Farrell G, Sherman M, Williams B, Dhillon A, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000;46:562–8.Google Scholar
  9. 9.
    Schiff E, Karayalcin S, Grimm I, Perrillo R, Dienstag J, Husa P, Schalm S, et al. A placebo controlled study of lamivudine and interferon alpha-2b in patients with chronic hepatitis B who previously failed interferon therapy. Hepatology 1998;28S:388A.Google Scholar
  10. 10.
    Melegari M, Scaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998;27:628–33.PubMedCrossRefGoogle Scholar
  11. 11.
    Ono-Nita SK, Kato N, Shiratori Y, Masaki T, Lan KH, Carrilho FJ, Omata M. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: a study by in vitro full-length viral DNA transfection. Hepatology 1999;29:93945.CrossRefGoogle Scholar
  12. 12.
    Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999;30:567–72.PubMedCrossRefGoogle Scholar
  13. 13.
    Kim JW, Lee HS, Woo GH, Yoon JH, Jang JJ, Chi JG, Kim CY. Fatal submassive hepatic necrosis associated with tyrosine-methionine-aspartate-aspartate-motif mutation of hepatitis B virus after long-term lamivudine therapy. Clin Infect Dis 2001;33:403–5.PubMedCrossRefGoogle Scholar
  14. 14.
    Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. Factors predicting hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001;34(4 Pt 1):785–91.PubMedCrossRefGoogle Scholar
  15. 15.
    Gauthier J, Bourne EJ, Lutz MW, Crowther LM, Dienstag JL, Brown NA, Condreay LD. Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine. J Infect Dis 1999;180:1757–62.PubMedCrossRefGoogle Scholar
  16. 16.
    Garrett L, Dienstag JL, Gauthier J, Condreay L, Crowther L, Gelb L, Schiff E, et al. Hepatitis B e-antigen seroconversion in 2 patients with evidence of genotypic resistance following extended lamivudine treatment. Hepatology l997;26(4):1209A.Google Scholar
  17. 17.
    Wang P, Hong JH, Cooperwood JS, Chu CK. Recent advances in L-nucleosides: chemistry and biology. Antiviral Res 1998;40(1–2):19–44.PubMedCrossRefGoogle Scholar
  18. 18.
    Bryant ML, Bridges EG, Placidi L, Faraj A, Loi AG, Pierra C, Dukhan D, et al. Antiviral L-nucleosides specific for hepatitis B virus infection. Antimicrob Agents Chemother 2001;45:229–35.PubMedCrossRefGoogle Scholar
  19. 19.
    Lai CL, Lim SG, Yuen MF, Pow DM, Myers MW. L-DT: An ongoing phase I/Il dose escalation trial in patients with chronic HBV infection (NV-02B-001). J Hepatol 2002;34(Suppl 1):139A.Google Scholar
  20. 20.
    Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann HW, Han S, et al. International multicenter trial of LdT (telbivudine), alone and in combination with lamivudine for chronic hepatitis B: An interim analysis. Hepatology 2002;4(Pt 2):301A.Google Scholar
  21. 21.
    Schalm SW, Heathcote J, Cianciara J, Farrell G, Sherman M, Williams B, Dhillon A, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000;46:562–8.Google Scholar
  22. 22.
    Liaw YF, Tsai SL, Chien RN, Yeh CT, Chu CM. Prednisolone priming enhances Th 1 response and efficacy of subsequent lamivudine therapy in patients with chronic hepatitis B. Hepatology 2000;32:604–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Shaw T, Locarnini, S. Combination chemotherapy for hepatitis B virus: The final solution? Hepatology 2000;32:430–2.Google Scholar
  24. 24.
    Lai CL, Rosmawati M, Lao J, Vlierberghe HV, Anderson FH, Thomas N, DeHertogh D. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 2002;123:1831–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Yang H, Westland CE, Delaney WE, Heathcote EJ, Ho V, Fry J, Brosgart C, et al. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology 2002;36:464–73.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Japan 2004

Authors and Affiliations

  • Man-Fung Yuen
    • 1
  • Ching-Lung Lai
    • 1
  1. 1.Division of Gastroenterology and Hepatology, Department of MedicineThe University of Hong Kong, Queen Mary HospitalHong Kong, China

Personalised recommendations